vs
Side-by-side financial comparison of APPFOLIO INC (APPF) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $262.2M, roughly 1.1× APPFOLIO INC). APPFOLIO INC runs the higher net margin — 16.2% vs 12.8%, a 3.3% gap on every dollar of revenue. On growth, APPFOLIO INC posted the faster year-over-year revenue change (20.4% vs -6.4%). Over the past eight quarters, APPFOLIO INC's revenue compounded faster (15.3% CAGR vs 4.2%).
AppFolio, Inc. is an American company founded in 2006 that offers software-as-a-service (SaaS) applications and services to the real estate industry.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
APPF vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $262.2M | $295.9M |
| Net Profit | $42.4M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | 19.4% | 18.4% |
| Net Margin | 16.2% | 12.8% |
| Revenue YoY | 20.4% | -6.4% |
| Net Profit YoY | 35.2% | 68.3% |
| EPS (diluted) | $1.18 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $262.2M | — | ||
| Q4 25 | $248.2M | $295.9M | ||
| Q3 25 | $249.4M | — | ||
| Q2 25 | $235.6M | $317.0M | ||
| Q1 25 | $217.7M | $316.2M | ||
| Q4 24 | $203.7M | $297.0M | ||
| Q3 24 | $205.7M | $289.5M | ||
| Q2 24 | $197.4M | $306.1M |
| Q1 26 | $42.4M | — | ||
| Q4 25 | $39.9M | $38.0M | ||
| Q3 25 | $33.6M | — | ||
| Q2 25 | $36.0M | $-17.7M | ||
| Q1 25 | $31.4M | $22.6M | ||
| Q4 24 | $102.7M | $34.9M | ||
| Q3 24 | $33.0M | $33.6M | ||
| Q2 24 | $29.7M | $40.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | 19.4% | — | ||
| Q4 25 | 17.6% | 18.4% | ||
| Q3 25 | 14.1% | — | ||
| Q2 25 | 17.2% | -7.5% | ||
| Q1 25 | 15.5% | 12.2% | ||
| Q4 24 | 11.3% | 16.0% | ||
| Q3 24 | 20.7% | 13.8% | ||
| Q2 24 | 18.3% | 15.0% |
| Q1 26 | 16.2% | — | ||
| Q4 25 | 16.1% | 12.8% | ||
| Q3 25 | 13.5% | — | ||
| Q2 25 | 15.3% | -5.6% | ||
| Q1 25 | 14.4% | 7.1% | ||
| Q4 24 | 50.4% | 11.7% | ||
| Q3 24 | 16.0% | 11.6% | ||
| Q2 24 | 15.0% | 13.3% |
| Q1 26 | $1.18 | — | ||
| Q4 25 | $1.10 | $0.24 | ||
| Q3 25 | $0.93 | — | ||
| Q2 25 | $0.99 | $-0.11 | ||
| Q1 25 | $0.86 | $0.14 | ||
| Q4 24 | $2.79 | $0.22 | ||
| Q3 24 | $0.90 | $0.21 | ||
| Q2 24 | $0.81 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $147.4M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $470.2M | $2.0B |
| Total Assets | $580.6M | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $147.4M | — | ||
| Q4 25 | $107.0M | $172.9M | ||
| Q3 25 | $76.1M | — | ||
| Q2 25 | $73.5M | $162.2M | ||
| Q1 25 | $56.9M | $140.7M | ||
| Q4 24 | $42.5M | $177.5M | ||
| Q3 24 | $62.4M | $187.5M | ||
| Q2 24 | $59.6M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | $470.2M | — | ||
| Q4 25 | $542.6M | $2.0B | ||
| Q3 25 | $498.9M | — | ||
| Q2 25 | $455.6M | $1.9B | ||
| Q1 25 | $462.1M | $2.0B | ||
| Q4 24 | $519.3M | $2.1B | ||
| Q3 24 | $412.8M | $2.1B | ||
| Q2 24 | $371.4M | $2.1B |
| Q1 26 | $580.6M | — | ||
| Q4 25 | $689.0M | $2.5B | ||
| Q3 25 | $640.5M | — | ||
| Q2 25 | $567.4M | $2.6B | ||
| Q1 25 | $564.7M | $2.6B | ||
| Q4 24 | $626.7M | $2.7B | ||
| Q3 24 | $523.3M | $2.7B | ||
| Q2 24 | $479.3M | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $34.3M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 0.81× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $34.3M | — | ||
| Q4 25 | $65.0M | — | ||
| Q3 25 | $86.0M | — | ||
| Q2 25 | $52.6M | $98.2M | ||
| Q1 25 | $38.5M | $41.1M | ||
| Q4 24 | $36.6M | $84.3M | ||
| Q3 24 | $57.8M | $63.9M | ||
| Q2 24 | $50.9M | $75.5M |
| Q1 26 | — | — | ||
| Q4 25 | $63.7M | — | ||
| Q3 25 | $84.7M | — | ||
| Q2 25 | $52.4M | $93.3M | ||
| Q1 25 | $38.2M | $31.0M | ||
| Q4 24 | $36.4M | $77.5M | ||
| Q3 24 | $57.4M | $54.7M | ||
| Q2 24 | $50.8M | $57.5M |
| Q1 26 | — | — | ||
| Q4 25 | 25.7% | — | ||
| Q3 25 | 34.0% | — | ||
| Q2 25 | 22.2% | 29.4% | ||
| Q1 25 | 17.6% | 9.8% | ||
| Q4 24 | 17.9% | 26.1% | ||
| Q3 24 | 27.9% | 18.9% | ||
| Q2 24 | 25.8% | 18.8% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | — | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.1% | 1.5% | ||
| Q1 25 | 0.1% | 3.2% | ||
| Q4 24 | 0.1% | 2.3% | ||
| Q3 24 | 0.2% | 3.2% | ||
| Q2 24 | 0.0% | 5.9% |
| Q1 26 | 0.81× | — | ||
| Q4 25 | 1.63× | — | ||
| Q3 25 | 2.56× | — | ||
| Q2 25 | 1.46× | — | ||
| Q1 25 | 1.23× | 1.82× | ||
| Q4 24 | 0.36× | 2.42× | ||
| Q3 24 | 1.75× | 1.90× | ||
| Q2 24 | 1.71× | 1.86× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
APPF
| Value Added Services | $201.4M | 77% |
| Subscription Services | $58.2M | 22% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
